Evidence mapPaperPMID 24824891Full record

ReviewCurrent opinion in HIV and AIDS2014

HIV and aging: emerging research issues.

Peter W Hunt

Abstract readReview
In one paragraph

Review in Current opinion in HIV and AIDS, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Association between HIV and Prevalent Hypertension and Diabetes Mellitus in South Africa: Analysis of a Nationally Representative Cross-Sectional Survey.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Frailty in people living with HIV.AIDS research and therapy · 2018
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Peter W HuntSFGH HIV/AIDS Division, University of California, San Francisco, California, USA.

Funding

TECHNOLOGY AND INFORMATION EXCHANGE COREP30MH062246 · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2001 to 2025
$12.5M
TB PREVENTION AND HIV IN THE HOMELESS--AN INTERVENTIONR01MH054907 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 1995 to 2005
$8.9M
CFAR Network of Integrated Clinical Systems (CNICS)R24AI067039 · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2025 to 2025
$6.4M
NIAID NIH HHS R01 AI110271NIAID NIH HHS R24 AI067039NIAID NIH HHS R56 AI100765NIMH NIH HHS P30 MH062246NIMH NIH HHS R01 MH054907NIMH NIH HHS R01 MH54907-1S1
6 · The paper itself

Abstract

purpose of reviewIt is now widely accepted that HIV-infected individuals remain at a higher risk for mortality and age-related morbidities than the general population, but several unresolved issues need to be addressed by the research community in the coming years to further improve the health of HIV-infected individuals in the modern treatment era. RECENT

findingsAlthough recent studies have helped to better define the contribution of HIV to life expectancy and morbidity in the modern antiretroviral therapy (ART) era, questions remain about the generalizability of these findings to a future HIV-infected population that is expected to be much older. Furthermore, although a consensus has emerged that the persistent inflammatory state contributes to morbidity and mortality in this setting, the relative contributions of this process, health-related behaviours, comorbidities and medication toxicities remain incompletely understood. Lastly, significant uncertainty remains over the root causes of the persistent inflammatory state, the specific immunologic pathways to target with interventions and the most appropriate biomarkers to use for surrogate outcomes in pilot trials of immune-based interventions. SUMMARY: Each of these issues will be addressed in this review, highlighting recently published and presented studies that inform the discussion, and recommendations will be made for prioritizing the future research agenda.

Indexed as

AgingComorbidityBiomedical ResearchHIV InfectionsHumans

Identifiers

PMID24824891
PMCPMC4138123

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.